[Featured Stock] Green Cross MS Rises Over 12% on Monkeypox Skin Infection Cases Increase
[Asia Economy Reporter Kwon Jae-hee] Green Cross MS, a stock related to 'monkeypox,' is showing strong performance in early trading on the 24th. As human infection cases of 'monkeypox' have been discovered worldwide, attention is returning to bio stocks that had been quiet since the COVID-19 endemic.
According to the Korea Exchange on the 24th, as of 10:02 AM, Green Cross MS is trading at 9,810 KRW, up 12.24% compared to the previous trading day. Green Cross MS also closed the previous day at 8,740 KRW, up 25.57% from the previous trading day.
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Green Cross MS is classified as a monkeypox-related stock due to its past research history in developing an attenuated smallpox vaccine. Currently, monkeypox cases have been reported in 15 countries. Although similar to smallpox, it is known to have relatively lower transmissibility and severity. Major symptoms include fever, chills, and muscle pain, with characteristic vesicular rashes similar to chickenpox appearing primarily on the hands and throughout the body.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
